エピソード

  • GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy

    GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy
    2025/07/07
    What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment? In part 2 of this 2-part series, moderator Judy Kim, MD, and panelists Rishi Singh, MD; Deepak Sambhara, MD, and Sunir Garg, MD, examine answers to these questions.
    続きを読む 一部表示
    11 分
  • GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates

    GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates
    2025/07/07
    How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion.
    続きを読む 一部表示
    7 分
  • Photobiomodulation for Age-related Macular Degeneration

    Photobiomodulation for Age-related Macular Degeneration
    2025/06/20
    What conclusions can be drawn from the LIGHTSITE III study examining photobiomodulation for dry AMD? Moderator Barton Blackorby, MD, sits down with panelists Hong-Uyen Hua, MD, and Louis Cai, MD, to examine a recent opinion piece published in JAMA Ophthalmology exploring what researchers can (and cannot) confidently conclude based on the study’s data.
    続きを読む 一部表示
    19 分
  • Duke AVS Clips: PVR, DR, Imaging, and MTM

    Duke AVS Clips: PVR, DR, Imaging, and MTM
    2025/06/12
    Duke faculty interview key lecturers from the 2025 Duke AVS Course about their podium talks. Jason Hsu, MD, discusses the best ways to manage proliferative vitreoretinopathy, Majda Hadziahmetovic, MD, shares new data on the effect of GLP-1 receptor agonists on diabetic retinopathy, Aleksandra V. Rachitskaya, MD, explains the value of multimodal Imaging in adults with a history of prematurity, and Gavin Tan, MD, PhD, FRCSed, discusses management approaches for myopic tractional maculopathy and macular holes.
    続きを読む 一部表示
    18 分
  • Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI

    Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI
    2025/06/09
    Faculty from the 2025 Duke AVS Course ask key lecturers to share pearls from their presentations. Lejla Vajzovic, MD, discusses various pediatric retinal conditions that can manifest later in life, Jason Fan, MD, explains trends in anesthesia use for open-globe surgery, and Glenn J. Jaffe, MD, examines the role of AI in retina clinical trials.
    続きを読む 一部表示
    12 分
  • Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs

    Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs
    2025/06/05
    During the 2025 Duke AVS Course, Duke faculty sat down with several key lecturers to discuss their presentations. Avni P. Finn, MD, MBA, discussed her experiences delivering subretinal gene therapy, David Zacks, MD, PhD, explored important factors in retinal detachment repair, Xi Chen, MD, PhD, highlighted the various surgical approaches for young patients who present without a posterior vitreous detachment, and Yannek I. Leiderman, MD, PhD, provided pearls for scleral fixation of secondary IOLs.
    続きを読む 一部表示
    17 分
  • ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

    ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data
    2025/05/29
    Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a BETTER study, which assessed the use of the anti-fibrosis agent ISTH0036 in patients with wet AMD and DME. And Diana Do, MD, sits down to review data from the LIGHTSITE IIIB study, which examined whether patients who underwent photobiomodulation therapy realized any benefit after re-administration following a 13-month washout period. Did the break in treatment lead to irreversible vision loss? Or were patients able experience a benefit after taking more than a year off? We have the answers in this episode.
    続きを読む 一部表示
    24 分
  • ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

    ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline
    2025/05/22
    Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic’s real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-dose aflibercept (Eylea HD, Regeneron). What were the differences—and did they really matter? Also, Robert Wang, MD, helped us understand the state of play in the TKI pipeline as he shared data from the phase 2b ODYSSEY study. What are the latest data on CLX-AX (Clearside Biomedcial)? And where does it stack up against the other TKIs in the pipeline? Stick with us to find out.
    続きを読む 一部表示
    23 分